Protokinetix Contracted to Produce AAGP™ for New Product Launch

ProtoKinetix Inc. (PKTX) is pleased to announce their first commercial contract to manufacture and provide AAGP™ as the key active ingredient in a topical anti-inflammatory cream. This new product is expected to be launched within the next few months by the manufacturer of IB Relief, a leader in sports injury relief.  The launch will be greatly enhanced by the use of proven channels of distribution to maximize their share of this multi-billion dollar market.

MEKT, LLC, the parent company that produces IB Relief, is a privately held pharmaceutical firm that specializes in topical cream products for pain management. This market, in the U.S. alone, is a $22 billion business growing at 6.6% yearly. MEKT entered into a License Agreement with ProtoKinetix after an extensive evaluation of the testing that has been completed on AAGP™. The formulation and testing of this new product will commence within the next month.

Ross Senior, President and CEO of ProtoKinetix states, “this will be the first of many commercial applications for the powerful and versatile family of AAGP™ molecules. The list of companies actively conducting trials using AAGP™ is growing.”

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Mr. Ross L. Senior, President and CEO

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887